New PCI innovations are being adopted globally to support better acute and long-term patient outcomes. 

Bioadaptor technology is one such innovation and serves as an alternative to drug-eluting stents. The coronary implant is designed to unlock 6 months after PCI and enable adaptive remodeling and a restoration to a more natural state, while still providing dynamic support.

Hertz Contact intravascular lithotripsy (HC-IVL) is another newer PCI technology, offering calcium modification with a simpler workflow across calcium morphologies and in difficult-to-reach lesions.

Availability of advanced technologies for PCI varies by region. Some technologies are commercially available in Europe, the Middle East and Asia.

DynamX bioadaptor and LithiX Hertz Contact intravascular lithotripsy (HC-IVL) are both CE Marked.

Physicians are using both devices in clinical practice in many countries according to local regulatory approvals.

Yes. In addition to drug-eluting stents, alternatives include bioadaptor technology, which provides dynamic support for the diseased vessel without permanently caging the artery. This approach aims to improve long-term vessel health and reduce complications.

Unlike traditional drug-eluting stents that permanently cage the artery, the DynamX Coronary Bioadaptor is designed to restore vessel motion and adaptive function after the vessel heals. This bioadaptive technology allows the artery to regain pulsatility, compliance, and natural blood-flow dynamics over time.

PCI treatment is intended for patients with coronary artery disease. Advanced technologies are especially important for patient cases where traditional approaches may have limitations.

Treatment of complex lesions, blockage in the left anterior descending artery (LAD), and patients with acute coronary syndrome may have specific benefits for treatment with bioadaptive angioplasty.

Patients with eccentric, concentric or nodular calcium morphologies and patients with lesions in difficult to reach places, such as those with tortuous anatomy, may benefit from treatment with LithiX Hertz Contact intravascular lithotripsy. Treatment decisions are made by physicians based on individual patient needs.

PCI innovation is currently focused on addressing several persistent challenges in interventional cardiology, including:

• Coronary artery disease
• Calcified lesions that complicate PCI procedures
• Long-term complication rates

Elixir Medical’s innovations are designed to improve lesion preparation, restore natural vessel behavior, and support long-term patient outcomes.

Elixir Medical technologies are supported by a growing body of clinical evidence, including peer-reviewed publications, randomized controlled trials, and real-world clinical experience.

The DynamX® bioadaptor is supported by multiple peer-reviewed studies demonstrating safety, effectiveness, and durable long-term outcomes. This includes two randomized controlled trials, one of them a large-scale, multi-center study enrolling approximately 2,400 patients. Additional evidence includes physician-led case studies and both single-center and multi-center clinical experiences presented at major international cardiology conferences such as TCT and EuroPCR.

The LithiX™ Hertz Contact intravascular lithotripsy (HC-IVL) system is supported by peer-reviewed data demonstrating safety and effectiveness across a range of calcium morphologies and lesion types. Clinical results have shown consistent plaque fracture and stent expansion, validated using multiple intravascular imaging modalities. Supporting evidence also includes case studies and clinical experiences from both single and multi-site use, presented at leading conferences including TCT and EuroPCR.